Very little really. We are talking about 28,888,888 new ordinary shares giving us a total issued share capital now of 223,358,373 ordinary shares. The dilution is modest, just 13%. Also extra funding of £6.5 million is now in place for several years ahead.
The company uses less than £2 million a year to run its operations. This puts Scancell in a far stronger negotiating position with a potential buyer of the company. It now has the resources to play hardball.
The shares traded OTC here are exactly the same shares traded in London except they are priced in dollar equivalents.
News 
Market Data 
Discover 
